Update on the SNG001 drug, an INFbeta therapy for COVID-19 [electronic resource] / an interview with Stephen Holgate.
Material type:![Sound](/opac-tmpl/lib/famfamfam/MU.png)
Audio interview.
Title from title frames.
Contents: An overview of SNG001 therapy -- Findings of the phase 2 clinical trial -- Treatment potential at different stages of the disease -- Advantages of the treatment delivery mode and accessibility -- Potential use as a prophylaxis treatment -- Follow up clinical trials to be undertaken -- Other treatment settings for INFβ.
Access restricted to subscribers.
Mode of access: World Wide Web.